231 related articles for article (PubMed ID: 34040148)
1. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.
McLornan DP; Hernandez-Boluda JC; Czerw T; Cross N; Joachim Deeg H; Ditschkowski M; Moonim MT; Polverelli N; Robin M; Aljurf M; Conneally E; Hayden P; Yakoub-Agha I
Leukemia; 2021 Sep; 35(9):2445-2459. PubMed ID: 34040148
[TBL] [Abstract][Full Text] [Related]
2. European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party.
McLornan DP; Sirait T; Hernández-Boluda JC; Czerw T; Hayden P; Yakoub-Agha I
Curr Res Transl Med; 2021 Jan; 69(1):103267. PubMed ID: 33069640
[TBL] [Abstract][Full Text] [Related]
3. Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT.
Nabergoj M; Mauff K; Robin M; Kröger N; Angelucci E; Poiré X; Passweg J; Radujkovic A; Platzbecker U; Robinson S; Rambaldi A; Petersen SL; Stölzel F; Stelljes M; Ciceri F; Mayer J; Ladetto M; de Wreede LC; Koster L; Hayden PJ; Czerw T; Hernández-Boluda JC; McLornan D; Chalandon Y; Yakoub-Agha I
Bone Marrow Transplant; 2021 Aug; 56(8):1944-1952. PubMed ID: 33824436
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.
Hernández-Boluda JC; Eikema DJ; Koster L; Kröger N; Robin M; de Witte M; Finke J; Finazzi MC; Broers A; Raida L; Schaap N; Chiusolo P; Verbeek M; Hazenberg CLE; Halaburda K; Kulagin A; Labussière-Wallet H; Gedde-Dahl T; Rabitsch W; Raj K; Drozd-Sokolowska J; Battipaglia G; Polverelli N; Czerw T; Yakoub-Agha I; McLornan DP
Bone Marrow Transplant; 2023 Dec; 58(12):1357-1367. PubMed ID: 37679647
[TBL] [Abstract][Full Text] [Related]
5. Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.
McLornan DP; Szydlo R; Robin M; van Biezen A; Koster L; Blok HJP; Van Lint MT; Finke J; Vitek A; Carlson K; Griskevicius L; Holler E; Itälä-Remes M; Schaap M; Socié G; Bay JO; Beguin Y; Bruno B; Cornelissen JJ; Gedde-Dahl T; Ljungman P; Rubio MT; Yakoub-Agha I; Klyuchnikov E; Olavarria E; Chalandon Y; Kröger N
Br J Haematol; 2018 Aug; 182(3):418-422. PubMed ID: 29808926
[TBL] [Abstract][Full Text] [Related]
6. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.
Polverelli N; Hernández-Boluda JC; Czerw T; Barbui T; D'Adda M; Deeg HJ; Ditschkowski M; Harrison C; Kröger NM; Mesa R; Passamonti F; Palandri F; Pemmaraju N; Popat U; Rondelli D; Vannucchi AM; Verstovsek S; Robin M; Colecchia A; Grazioli L; Damiani E; Russo D; Brady J; Patch D; Blamek S; Damaj GL; Hayden P; McLornan DP; Yakoub-Agha I
Lancet Haematol; 2023 Jan; 10(1):e59-e70. PubMed ID: 36493799
[TBL] [Abstract][Full Text] [Related]
7. Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.
Ecsedi M; Schmohl J; Zeiser R; Drexler B; Halter J; Medinger M; Duyster J; Kanz L; Passweg J; Finke J; Bethge W; Lengerke C
Ann Hematol; 2016 Oct; 95(10):1627-36. PubMed ID: 27480090
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
Hernández-Boluda JC; Pereira A; Kröger N; Cornelissen JJ; Finke J; Beelen D; de Witte M; Wilson K; Platzbecker U; Sengeloev H; Blaise D; Einsele H; Sockel K; Krüger W; Lenhoff S; Salaroli A; Martin H; García-Gutiérrez V; Pavone V; Alvarez-Larrán A; Raya JM; Zinger N; Gras L; Hayden P; Czerw T; P McLornan D; Yakoub-Agha I
Am J Hematol; 2021 Oct; 96(10):1186-1194. PubMed ID: 34152630
[TBL] [Abstract][Full Text] [Related]
9. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.
Kharfan-Dabaja MA; Kumar A; Ayala E; Aljurf M; Nishihori T; Marsh R; Burroughs LM; Majhail N; Al-Homsi AS; Al-Kadhimi ZS; Bar M; Bertaina A; Boelens JJ; Champlin R; Chaudhury S; DeFilipp Z; Dholaria B; El-Jawahri A; Fanning S; Fraint E; Gergis U; Giralt S; Hamilton BK; Hashmi SK; Horn B; Inamoto Y; Jacobsohn DA; Jain T; Johnston L; Kanate AS; Kansagra A; Kassim A; Kean LS; Kitko CL; Knight-Perry J; Kurtzberg J; Liu H; MacMillan ML; Mahmoudjafari Z; Mielcarek M; Mohty M; Nagler A; Nemecek E; Olson TS; Oran B; Perales MA; Prockop SE; Pulsipher MA; Pusic I; Riches ML; Rodriguez C; Romee R; Rondon G; Saad A; Shah N; Shaw PJ; Shenoy S; Sierra J; Talano J; Verneris MR; Veys P; Wagner JE; Savani BN; Hamadani M; Carpenter PA
Transplant Cell Ther; 2021 Aug; 27(8):642-649. PubMed ID: 34304802
[TBL] [Abstract][Full Text] [Related]
10. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
Raj K; Eikema DJ; McLornan DP; Olavarria E; Blok HJ; Bregante S; Ciceri F; Passweg J; Ljungman P; Schaap N; Carlson K; Zuckerman T; de Wreede LC; Volin L; Koc Y; Diez-Martin JL; Brossart P; Wolf D; Blaise D; Bartolomeo PD; Vitek A; Robin M; Yakoub-Agha I; Chalandon Y; Kroger N
Biol Blood Marrow Transplant; 2019 Mar; 25(3):522-528. PubMed ID: 30408564
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Lussana F; Rambaldi A; Finazzi MC; van Biezen A; Scholten M; Oldani E; Carobbio A; Iacobelli S; Finke J; Nagler A; Volin L; Lamy T; Arnold R; Mohty M; Michallet M; de Witte T; Olavarria E; Kröger N
Haematologica; 2014 May; 99(5):916-21. PubMed ID: 24389309
[TBL] [Abstract][Full Text] [Related]
12. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
[TBL] [Abstract][Full Text] [Related]
13. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.
Hernández-Boluda JC; Pereira A; Kröger N; Beelen D; Robin M; Bornhäuser M; Angelucci E; Vitek A; Blau IW; Niittyvuopio R; Finke J; Cornelissen JJ; Passweg J; Dreger P; Petersen E; Kanz L; Sanz J; Zuckerman T; Zinger N; Iacobelli S; Hayden P; Czerw T; McLornan D; Yakoub-Agha I
Leukemia; 2021 Jan; 35(1):215-224. PubMed ID: 32286544
[TBL] [Abstract][Full Text] [Related]
14. Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis.
Cyriac S; Prem S; Salas MQ; Chen S; Al-Shaibani Z; Lam W; Law A; Gupta V; Michelis FV; Kim DDH; Lipton J; Kumar R; Mattsson J; Viswabandya A
Eur J Haematol; 2021 Nov; 107(5):517-528. PubMed ID: 34260760
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT.
Sureda A; Carpenter PA; Bacigalupo A; Bhatt VR; de la Fuente J; Ho A; Kean L; Lee JW; Sánchez-Ortega I; Savani BN; Schetelig J; Stadtmauer EA; Takahashi Y; Atsuta Y; Koreth J; Kröger N; Ljungman P; Okamoto S; Popat U; Soiffer R; Stefanski HE; Kharfan-Dabaja MA
Bone Marrow Transplant; 2024 Jun; 59(6):832-837. PubMed ID: 38443706
[TBL] [Abstract][Full Text] [Related]
17. Correction: Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.
McLornan DP; Hernandez-Boluda JC; Czerw T; Cross N; Joachim Deeg H; Ditschkowski M; Moonim MT; Polverelli N; Robin M; Aljurf M; Conneally E; Hayden P; Yakoub-Agha I
Leukemia; 2021 Dec; 35(12):3625. PubMed ID: 34471230
[No Abstract] [Full Text] [Related]
18. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
[TBL] [Abstract][Full Text] [Related]
19. 2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management.
Ali H; Bacigalupo A
Am J Hematol; 2021 Nov; 96(11):1532-1538. PubMed ID: 34536293
[TBL] [Abstract][Full Text] [Related]
20. Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT.
Czerw T; Iacobelli S; Malpassuti V; Koster L; Kröger N; Robin M; Maertens J; Chevallier P; Watz E; Poiré X; Snowden JA; Kuball J; Kinsella F; Blaise D; Reményi P; Mear JB; Cammenga J; Rubio MT; Maury S; Daguindau E; Finnegan D; Hayden P; Hernández-Boluda JC; McLornan D; Yakoub-Agha I
Bone Marrow Transplant; 2022 Feb; 57(2):261-270. PubMed ID: 34853433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
